Bio Protocol@BioProtocol
Claude almost killed our AI Developer.
Not literally.
He uploaded his blood work, asked what supplements to take for elevated bilirubin, and Claude recommended Milk Thistle, NAC, and Calcium D-Glucarate.
For his condition, that stack could have made things worse.
Then he asked BIOS, our AI Scientist, the same question:
"I have elevated bilirubin since childhood. I train 5 times a week. What supplements can I actually take?"
BIOS got to work.
It identified the condition from the lab panel. Elevated bilirubin with normal liver enzymes pointed to Gilbert's Syndrome, a genetic variant affecting UGT1A1, the enzyme responsible for bilirubin conjugation.
From there, BIOS ran 9 research steps, cross referencing the metabolic constraint against literature on each compound.
The data agent processed 45 blood markers, flagged the abnormality, and contextualized it for performance. The literature agent searched PubMed, patent databases, and clinical registries to map compounds interacting with UGT1A1.
What it found would not come from a standard search.
Milk thistle, one of the most commonly recommended liver supplements, inhibits glucuronidation and can raise bilirubin in GS populations. Green tea extract showed an IC50 of 7.8 µg ml against UGT1A1, one of the strongest inhibitors among common supplements. Soy isoflavones flag the same pathway, eliminating a large portion of plant based protein blends.
These are not obscure findings. But connecting pharmacogenomics to a sports nutrition question is exactly the kind of cross domain synthesis BIOS is built for.
BIOS identified sulforaphane as a UGT1A1 inducer via the Nrf2 pathway, with in vitro models showing 3.7 fold enzyme induction, up to 12 fold with apigenin. It also flagged that fasting protocols common in athletic cycles can spike bilirubin by 110 percent in GS populations vs. 60 percent in healthy controls. Consistent caloric intake is not a lifestyle suggestion here.
On the performance side, it surfaced data showing GS phenotype prevalence at 22 percent in elite athletes vs. 9.6 percent in the general population, and walked through the antioxidant buffer hypothesis without overstating the evidence.
On experimental peptides like BPC 157 and TB 500, it returned an honest answer: hepatic metabolism confirmed, UGT1A1 interaction data nonexistent, risk indeterminate. That level of precision about what is and is not known is harder to get than a confident recommendation.
This is the kind of question that gets a generic answer everywhere else. A physician says it is benign. A nutritionist recommends the same stack.
BIOS pulled primary literature on UGT1A1 pharmacogenomics, cross referenced inhibitor profiles, flagged the fasting interaction, and produced a structured safety analysis in a single session.
BIOS session:
chat.bio.xyz/chats/fxSYcu1y…
Claude session:
t3.chat/share/clzobz9r…
This is not medical advice.
Decisions should be made with a qualified professional.
